Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bonadonna, G.
Right arrow Articles by Zambetti, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bonadonna, G.
Right arrow Articles by Zambetti, M.

Journal of Clinical Oncology, Vol 16, 93-100, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute

G Bonadonna, P Valagussa, C Brambilla, L Ferrari, A Moliterni, M Terenziani and M Zambetti
Department of Medicine, Istituto Nazionale Tumori, Milan, Italy. bonadonna@istitutotumori.mi.it

PURPOSE: Primary chemotherapy was administered to patients with tumors that measured > or = 2.5 cm in largest diameter to decrease the size of the primary tumor and allow for effective local and distant control while avoiding mastectomy. PATIENTS AND METHODS: Two prospective nonrandomized studies were performed that used different regimens of primary chemotherapy followed by breast-sparing surgery in the presence of objective tumor remission. Additional postoperative chemotherapy was given to women at high risk of disease relapse. The median follow-up duration was 65 months. RESULTS: A total of 536 assessable patients were enrolled, and the main characteristics were fairly comparable between the two trials. Following primary chemotherapy, 85% of patients could be subjected to breast-sparing surgery; in 14 patients (3%), surgical specimens failed to show any residual neoplastic cell. In the final multivariate analysis, the histologically assessed extent of axillary node involvement (P < .001), as well as degree of response to primary chemotherapy (P = .034), represented the significant variables able to influence 8-year relapse-free survival. In women subjected to a breast-conserving approach, the cumulative risk of local relapse as first event alone was 6.8% (95% confidence interval, 3.9% to 8.8%). CONCLUSION: Current findings indicate that primary chemotherapy can be safely administered in women with large tumors (>5.0 cm) and can allow breast-sparing surgery in a high fraction of patients (62%). However, to assess effectively the worthiness of this approach on long-term results, properlyconceived large randomized studies with newer and more effective drug regimens are warranted.


This article has been cited by other articles:


Home page
 The OncologistHome page
F. Penault-Llorca, C. Abrial, I. Raoelfils, P. Chollet, A. Cayre, M.-A. Mouret-Reynier, E. Thivat, F. Mishellany, P. Gimbergues, and X. Durando
Changes and Predictive and Prognostic Value of the Mitotic Index, Ki-67, Cyclin D1, and Cyclo-oxygenase-2 in 710 Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Oncologist, December 1, 2008; 13(12): 1235 - 1245.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
C. F. J. M. Peeters, R. M. W. de Waal, T. Wobbes, and T. J. M. Ruers
Metastatic Dormancy Imposed by the Primary Tumor: Does it Exist in Humans?
Ann. Surg. Oncol., November 1, 2008; 15(11): 3308 - 3315.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Berruti, M. P. Brizzi, D. Generali, M. Ardine, L. Dogliotti, P. Bruzzi, and A. Bottini
Presurgical Systemic Treatment of Nonmetastatic Breast Cancer: Facts and Open Questions
Oncologist, November 1, 2008; 13(11): 1137 - 1148.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M.-L. W. Ah-See, A. Makris, N. J. Taylor, M. Harrison, P. I. Richman, R. J. Burcombe, J. J. Stirling, J. A. d'Arcy, D. J. Collins, M. R. Pittam, et al.
Early Changes in Functional Dynamic Magnetic Resonance Imaging Predict for Pathologic Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
Clin. Cancer Res., October 15, 2008; 14(20): 6580 - 6589.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. S. Jeruss, E. A. Mittendorf, S. L. Tucker, A. M. Gonzalez-Angulo, T. A. Buchholz, A. A. Sahin, J. N. Cormier, A. U. Buzdar, G. N. Hortobagyi, and K. K. Hunt
Staging of Breast Cancer in the Neoadjuvant Setting
Cancer Res., August 15, 2008; 68(16): 6477 - 6481.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
P. Gimbergues, C. Abrial, X. Durando, G. Le Bouedec, F. Cachin, F. Penault-Llorca, M. A. Mouret-Reynier, F. Kwiatkowski, J. Maublant, A. Tchirkov, et al.
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy Is Accurate in Breast Cancer Patients with a Clinically Negative Axillary Nodal Status at Presentation
Ann. Surg. Oncol., May 1, 2008; 15(5): 1316 - 1321.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Rastogi, S. J. Anderson, H. D. Bear, C. E. Geyer, M. S. Kahlenberg, A. Robidoux, R. G. Margolese, J. L. Hoehn, V. G. Vogel, S. R. Dakhil, et al.
Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
J. Clin. Oncol., February 10, 2008; 26(5): 778 - 785.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. R. Gralow, H. J. Burstein, W. Wood, G. N. Hortobagyi, L. Gianni, G. von Minckwitz, A. U. Buzdar, I. E. Smith, W. F. Symmans, B. Singh, et al.
Preoperative Therapy in Invasive Breast Cancer: Pathologic Assessment and Systemic Therapy Issues in Operable Disease
J. Clin. Oncol., February 10, 2008; 26(5): 814 - 819.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. S. Jeruss, E. A. Mittendorf, S. L. Tucker, A. M. Gonzalez-Angulo, T. A. Buchholz, A. A. Sahin, J. N. Cormier, A. U. Buzdar, G. N. Hortobagyi, and K. K. Hunt
Combined Use of Clinical and Pathologic Staging Variables to Define Outcomes for Breast Cancer Patients Treated With Neoadjuvant Therapy
J. Clin. Oncol., January 10, 2008; 26(2): 246 - 252.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. F. Symmans, F. Peintinger, C. Hatzis, R. Rajan, H. Kuerer, V. Valero, L. Assad, A. Poniecka, B. Hennessy, M. Green, et al.
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
J. Clin. Oncol., October 1, 2007; 25(28): 4414 - 4422.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B Brenner, M. Shah, M. Karpeh, M Gonen, M. Brennan, D. Coit, D. Klimstra, L. Tang, and D. Kelsen
A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer
Ann. Onc., September 1, 2006; 17(9): 1404 - 1411.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. D. Bear, S. Anderson, R. E. Smith, C. E. Geyer Jr, E. P. Mamounas, B. Fisher, A. M. Brown, A. Robidoux, R. Margolese, M. S. Kahlenberg, et al.
Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27
J. Clin. Oncol., May 1, 2006; 24(13): 2019 - 2027.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Tinari, R. Lattanzio, C. Natoli, E. Cianchetti, D. Angelucci, E. Ricevuto, C. Ficorella, P. Marchetti, S. Alberti, M. Piantelli, et al.
Changes of Topoisomerase II{alpha} Expression in Breast Tumors after Neoadjuvant Chemotherapy Predicts Relapse-Free Survival
Clin. Cancer Res., March 1, 2006; 12(5): 1501 - 1506.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Gianni, J. Baselga, W. Eiermann, V. Guillem Porta, V. Semiglazov, A. Lluch, M. Zambetti, D. Sabadell, G. Raab, A. Llombart Cussac, et al.
Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy
Clin. Cancer Res., December 15, 2005; 11(24): 8715 - 8721.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Xu, L. Yao, T. Ouyang, J. Li, T. Wang, Z. Fan, B. Lin, Y. Lu, and Y. Xie
p53 Codon 72 Polymorphism Predicts the Pathologic Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer
Clin. Cancer Res., October 15, 2005; 11(20): 7328 - 7333.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Gianni, M. Zambetti, K. Clark, J. Baker, M. Cronin, J. Wu, G. Mariani, J. Rodriguez, M. Carcangiu, D. Watson, et al.
Gene Expression Profiles in Paraffin-Embedded Core Biopsy Tissue Predict Response to Chemotherapy in Women With Locally Advanced Breast Cancer
J. Clin. Oncol., October 10, 2005; 23(29): 7265 - 7277.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. Bonnefoi
'Small' randomised neo-adjuvant chemotherapy trials in breast cancer reporting on pathological response: more harm than good?
Ann. Onc., September 1, 2005; 16(9): 1407 - 1410.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
L. A. Carey, R. Metzger, E. C. Dees, F. Collichio, C. I. Sartor, D. W. Ollila, N. Klauber-DeMore, J. Halle, L. Sawyer, D. T. Moore, et al.
American Joint Committee on Cancer Tumor-Node-Metastasis Stage After Neoadjuvant Chemotherapy and Breast Cancer Outcome
J Natl Cancer Inst, August 3, 2005; 97(15): 1137 - 1142.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
S. C. Partridge, J. E. Gibbs, Y. Lu, L. J. Esserman, D. Tripathy, D. S. Wolverton, H. S. Rugo, E. S. Hwang, C. A. Ewing, and N. M. Hylton
MRI Measurements of Breast Tumor Volume Predict Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival
Am. J. Roentgenol., June 1, 2005; 184(6): 1774 - 1781.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Hannemann, H. M. Oosterkamp, C. A.J. Bosch, A. Velds, L. F.A. Wessels, C. Loo, E. J. Rutgers, S. Rodenhuis, and M. J. van de Vijver
Changes in Gene Expression Associated With Response to Neoadjuvant Chemotherapy in Breast Cancer
J. Clin. Oncol., May 20, 2005; 23(15): 3331 - 3342.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T.R. J. Evans, A. Yellowlees, E. Foster, H. Earl, D. A. Cameron, A. W. Hutcheon, R. E. Coleman, T. Perren, C. J. Gallagher, M. Quigley, et al.
Phase III Randomized Trial of Doxorubicin and Docetaxel Versus Doxorubicin and Cyclophosphamide As Primary Medical Therapy in Women With Breast Cancer: An Anglo-Celtic Cooperative Oncology Group Study
J. Clin. Oncol., May 1, 2005; 23(13): 2988 - 2995.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Cristofanilli, A. Gonzalez-Angulo, N. Sneige, S.-W. Kau, K. Broglio, R. L. Theriault, V. Valero, A. U. Buzdar, H. Kuerer, T. A. Buccholz, et al.
Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes
J. Clin. Oncol., January 1, 2005; 23(1): 41 - 48.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. Dieras, P. Fumoleau, G. Romieu, M. Tubiana-Hulin, M. Namer, L. Mauriac, J.-P. Guastalla, E. Pujade-Lauraine, P. Kerbrat, P. Maillart, et al.
Randomized Parallel Study of Doxorubicin Plus Paclitaxel and Doxorubicin Plus Cyclophosphamide As Neoadjuvant Treatment of Patients With Breast Cancer
J. Clin. Oncol., December 15, 2004; 22(24): 4958 - 4965.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. Modlich, H.-B. Prisack, M. Munnes, W. Audretsch, and H. Bojar
Immediate Gene Expression Changes After the First Course of Neoadjuvant Chemotherapy in Patients with Primary Breast Cancer Disease
Clin. Cancer Res., October 1, 2004; 10(19): 6418 - 6431.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
J. Shen, V. Valero, T. A. Buchholz, S. E. Singletary, F. C. Ames, M. I. Ross, M. Cristofanilli, G. V. Babiera, F. Meric-Bernstam, B. Feig, et al.
Effective Local Control and Long-Term Survival in Patients with T4 Locally Advanced Breast Cancer Treated with Breast Conservation Therapy
Ann. Surg. Oncol., September 1, 2004; 11(9): 854 - 860.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. S. Mano and A. Awada
Primary chemotherapy for breast cancer: the evidence and the future
Ann. Onc., August 1, 2004; 15(8): 1161 - 1171.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. M. Chen, F. Meric-Bernstam, K. K. Hunt, H. D. Thames, M. J. Oswald, E. D. Outlaw, E. A. Strom, M. D. McNeese, H. M. Kuerer, M. I. Ross, et al.
Breast Conservation After Neoadjuvant Chemotherapy: The M.D. Anderson Cancer Center Experience
J. Clin. Oncol., June 15, 2004; 22(12): 2303 - 2312.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. G. Estevez and W. J. Gradishar
Evidence-Based Use of Neoadjuvant Taxane in Operable and Inoperable Breast Cancer
Clin. Cancer Res., May 15, 2004; 10(10): 3249 - 3261.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
I. E. Smith, R. P. A'Hern, G. A. Coombes, A. Howell, S. R. Ebbs, T. F. Hickish, M. E. R. O'Brien, J. L. Mansi, C. B. Wilson, A. C. Robinson, et al.
A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial
Ann. Onc., May 1, 2004; 15(5): 751 - 758.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. D. Bear
In Reply:
J. Clin. Oncol., May 1, 2004; 22(9): 1766 - 1767.
[Full Text] [PDF]

Home page
 CMAJHome page
T. Shenkier, L. Weir, M. Levine, I. Olivotto, T. Whelan, and L. Reyno
Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer
Can. Med. Assoc. J., March 16, 2004; 170(6): 983 - 994.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Ring, A. Webb, S. Ashley, W.H. Allum, S. Ebbs, G. Gui, N.P. Sacks, G. Walsh, and I.E. Smith
Is Surgery Necessary After Complete Clinical Remission Following Neoadjuvant Chemotherapy for Early Breast Cancer?
J. Clin. Oncol., December 15, 2003; 21(24): 4540 - 4545.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. D. Bear, S. Anderson, A. Brown, R. Smith, E. P. Mamounas, B. Fisher, R. Margolese, H. Theoret, A. Soran, D. L. Wickerham, et al.
The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27
J. Clin. Oncol., November 15, 2003; 21(22): 4165 - 4174.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Ganem, M. Tubiana-Hulin, P. Fumoleau, M. Combe, J.-L. Misset, J.-M. Vannetzel, T. Bachelot, L. R. De Ybarlucea, V. Lotz, B. Bendahmane, et al.
Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer
Ann. Onc., November 1, 2003; 14(11): 1623 - 1628.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
D. N. Danforth Jr, K. Cowan, R. Altemus, M. Merino, C. Chow, A. Berman, U. Chaudhry, C. Shriver, S. M. Steinberg, and J. Zujewski
Preoperative FLAC/Granulocyte-Colony-Stimulating Factor Chemotherapy for Stage II Breast Cancer: A Prospective Randomized Trial
Ann. Surg. Oncol., July 1, 2003; 10(6): 635 - 644.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Kaufmann, G. von Minckwitz, R. Smith, V. Valero, L. Gianni, W. Eiermann, A. Howell, S. D. Costa, P. Beuzeboc, M. Untch, et al.
International Expert Panel on the Use of Primary (Preoperative) Systemic Treatment of Operable Breast Cancer: Review and Recommendations
J. Clin. Oncol., July 1, 2003; 21(13): 2600 - 2608.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
H. D. Bear
Earlier Chemotherapy for Breast Cancer: Perhaps Too Late But Still Useful
Ann. Surg. Oncol., May 1, 2003; 10(4): 334 - 335.
[Full Text] [PDF]

Home page
 Ann OncolHome page
G. Mustacchi, R. Ceccherini, S. Milani, A. Pluchinotta, A. De Matteis, L. Maiorino, A. Farris, A. Scanni, and F. Sasso
Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial
Ann. Onc., March 1, 2003; 14(3): 414 - 420.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. C. Formenti, M. Volm, K. A. Skinner, D. Spicer, D. Cohen, E. Perez, A. C. Bettini, S. Groshen, C. Gee, B. Florentine, et al.
Preoperative Twice-Weekly Paclitaxel With Concurrent Radiation Therapy Followed by Surgery and Postoperative Doxorubicin-Based Chemotherapy in Locally Advanced Breast Cancer: A Phase I/II Trial
J. Clin. Oncol., March 1, 2003; 21(5): 864 - 870.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. G. Estevez, J. M. Cuevas, A. Anton, J. Florian, J. M. Lopez-Vega, A. Velasco, F. Lobo, A. Herrero, and J. Fortes
Weekly Docetaxel as Neoadjuvant Chemotherapy for Stage II and III Breast Cancer: Efficacy and Correlation with Biological Markers in a Phase II, Multicenter Study
Clin. Cancer Res., February 1, 2003; 9(2): 686 - 692.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Bonadonna, M. Zambetti, C. Bumma, M. Donadio, A. Bolognesi, G. Robustelli della Cuna, G. Ambrosini, G. Lelli, M. Mansutti, P. Verderio, et al.
Multimodal treatment with primary single-agent epirubicin in operable breast cancer: 5-year experience of the Michelangelo Cooperative Group
Ann. Onc., July 1, 2002; 13(7): 1049 - 1058.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Parton, S. Krajewski, I. Smith, M. Krajewska, C. Archer, M. Naito, R. Ahern, J. Reed, and M. Dowsett
Coordinate Expression of Apoptosis-associated Proteins in Human Breast Cancer before and during Chemotherapy
Clin. Cancer Res., July 1, 2002; 8(7): 2100 - 2108.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. C. Wolff and N. E. Davidson
Preoperative Therapy in Breast Cancer: Lessons from the Treatment of Locally Advanced Disease
Oncologist, June 1, 2002; 7(3): 239 - 245.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
K. I. Bland
Utilization of Sentinel Lymph Node Mapping to Determine Pathologic Outcomes for Patients Receiving Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer
Ann. Surg. Oncol., April 1, 2002; 9(3): 217 - 219.
[Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
V. Stearns, C. A. Ewing, R. Slack, M. F. Penannen, D. F. Hayes, and T. N. Tsangaris
Sentinel Lymphadenectomy After Neoadjuvant Chemotherapy for Breast Cancer May Reliably Represent the Axilla Except for Inflammatory Breast Cancer
Ann. Surg. Oncol., April 1, 2002; 9(3): 235 - 242.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. A. Buchholz, S. L. Tucker, L. Masullo, H. M. Kuerer, J. Erwin, J. Salas, D. Frye, E. A. Strom, M. D. McNeese, G. Perkins, et al.
Predictors of Local-Regional Recurrence After Neoadjuvant Chemotherapy and Mastectomy Without Radiation
J. Clin. Oncol., January 1, 2002; 20(1): 17 - 23.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. A. van der Hage, C. J.H. van de Velde, J.-P. Julien, M. Tubiana-Hulin, C. Vandervelden, and L. Duchateau
Preoperative Chemotherapy in Primary Operable Breast Cancer: Results From the European Organization for Research and Treatment of Cancer Trial 10902
J. Clin. Oncol., November 15, 2001; 19(22): 4224 - 4237.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
S. Demaria, M. D. Volm, R. L. Shapiro, H. T. Yee, R. Oratz, S. C. Formenti, F. Muggia, and W. F. Symmans
Development of Tumor-infiltrating Lymphocytes in Breast Cancer after Neoadjuvant Paclitaxel Chemotherapy
Clin. Cancer Res., October 1, 2001; 7(10): 3025 - 3030.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Rouzier, J.-M. Extra, M. Carton, M.-C. Falcou, A. Vincent-Salomon, A. Fourquet, P. Pouillart, and E. Bourstyn
Primary Chemotherapy for Operable Breast Cancer: Incidence and Prognostic Significance of Ipsilateral Breast Tumor Recurrence After Breast-Conserving Surgery
J. Clin. Oncol., September 15, 2001; 19(18): 3828 - 3835.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. von Minckwitz, S. D. Costa, G. Raab, J.-U. Blohmer, H. Eidtmann, J. Hilfrich, E. Merkle, C. Jackisch, G. Gademann, A. H. Tulusan, et al.
Dose-Dense Doxorubicin, Docetaxel, and Granulocyte Colony-Stimulating Factor Support With or Without Tamoxifen as Preoperative Therapy in Patients With Operable Carcinoma of the Breast: A Randomized, Controlled, Open Phase IIb Study
J. Clin. Oncol., August 1, 2001; 19(15): 3506 - 3515.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. F. Symmans, M. D. Volm, R. L. Shapiro, A. B. Perkins, A. Y. Kim, S. Demaria, H. T. Yee, H. McMullen, R. Oratz, P. Klein, et al.
Paclitaxel-induced Apoptosis and Mitotic Arrest Assessed by Serial Fine-Needle Aspiration: Implications for Early Prediction of Breast Cancer Response to Neoadjuvant Treatment
Clin. Cancer Res., December 1, 2000; 6(12): 4610 - 4617.
[Abstract] [Full Text]

Home page
 JNCI J Natl Cancer InstHome page
P. Pedrazzoli, A. S. Bianchi, M. Renga, and S. Siena
Re: Randomized Trial of High-Dose Chemotherapy and Blood Cell Autografts for High-Risk Primary Breast Carcinoma
J Natl Cancer Inst, August 2, 2000; 92(15): 1271 - 1272.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Bottini, A. Berruti, A. Bersiga, M. P. Brizzi, A. Brunelli, G. Gorzegno, B. DiMarco, S. Aguggini, G. Bolsi, F. Cirillo, et al.
p53 but not bcl-2 Immunostaining Is Predictive of Poor Clinical Complete Response to Primary Chemotherapy in Breast Cancer Patients
Clin. Cancer Res., July 1, 2000; 6(7): 2751 - 2758.
[Abstract] [Full Text]

Home page
 JCOHome page
A. C. Wolff and N. E. Davidson
Primary Systemic Therapy in Operable Breast Cancer
J. Clin. Oncol., April 7, 2000; 18(7): 1558 - 1569.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. C. Smith, A. E. Welch, A. W. Hutcheon, I. D. Miller, S. Payne, F. Chilcott, S. Waikar, T. Whitaker, A. K. Ah-See, O. Eremin, et al.
Positron Emission Tomography Using [18F]-Fluorodeoxy-D-Glucose to Predict the Pathologic Response of Breast Cancer to Primary Chemotherapy
J. Clin. Oncol., April 1, 2000; 18(8): 1676 - 1688.
[Abstract] [Full Text] [PDF]